Pharmacokinetic comparison of an angiotensin II receptor antagonist, telmisartan, in Japanese and western hypertensive patients using population pharmacokinetic method.

Shinji Tatami, Norio Yamamura, Akiko Sarashina, Chan Loi Yong, Takashi Igarashi, Yusuke Tanigawara

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The objectives of this study were to develop a population pharmacokinetic (PPK) model for telmisartan based on the pooled data obtained from the different racial populations and then to identify the factors that affect the pharmacokinetics of telmisartan for the comparison between the regions. A PPK model was established based on the data of 1343 subjects in 12 clinical trials. The PK profiles of telmisartan were described with a 2-compartment model with first-order absorption. The obtained model could predict the observed plasma concentrations well. This PPK model suggested that CL/F was a function of age, dose, gender, race, alcohol consumption and liver function. A marked difference was observed in the plasma concentration profiles between Japanese and other countries' subjects. However, the effect of the factor "race" on CL/F was not large. In the present PPK model, "trial condition" affected all PK parameters except for V(2)/F. The condition differences were in food condition and formulation (Japanese: fed, capsule, US and EU: fasted, tablet). The extent of difference in the plasma concentration profiles simulated for Japanese and Caucasian using the PPK model under the same demographic condition was comparable with the results of the food effect study performed previously in Japan. The findings suggest that the difference in the plasma concentration profiles between Japanese and other countries' subjects was mainly due to the difference of food intake conditions under which the clinical trials were performed.

Original languageEnglish
Pages (from-to)15-23
Number of pages9
JournalDrug Metabolism and Pharmacokinetics
Volume19
Issue number1
Publication statusPublished - 2004
Externally publishedYes

Fingerprint

Angiotensin Receptor Antagonists
Pharmacokinetics
Population
Clinical Trials
Food
Alcohol Drinking
Tablets
Capsules
telmisartan
Japan
Eating
Demography
Liver

Cite this

Pharmacokinetic comparison of an angiotensin II receptor antagonist, telmisartan, in Japanese and western hypertensive patients using population pharmacokinetic method. / Tatami, Shinji; Yamamura, Norio; Sarashina, Akiko; Yong, Chan Loi; Igarashi, Takashi; Tanigawara, Yusuke.

In: Drug Metabolism and Pharmacokinetics, Vol. 19, No. 1, 2004, p. 15-23.

Research output: Contribution to journalArticle

@article{4a668c7511ab4640a97cd818e2ec7453,
title = "Pharmacokinetic comparison of an angiotensin II receptor antagonist, telmisartan, in Japanese and western hypertensive patients using population pharmacokinetic method.",
abstract = "The objectives of this study were to develop a population pharmacokinetic (PPK) model for telmisartan based on the pooled data obtained from the different racial populations and then to identify the factors that affect the pharmacokinetics of telmisartan for the comparison between the regions. A PPK model was established based on the data of 1343 subjects in 12 clinical trials. The PK profiles of telmisartan were described with a 2-compartment model with first-order absorption. The obtained model could predict the observed plasma concentrations well. This PPK model suggested that CL/F was a function of age, dose, gender, race, alcohol consumption and liver function. A marked difference was observed in the plasma concentration profiles between Japanese and other countries' subjects. However, the effect of the factor {"}race{"} on CL/F was not large. In the present PPK model, {"}trial condition{"} affected all PK parameters except for V(2)/F. The condition differences were in food condition and formulation (Japanese: fed, capsule, US and EU: fasted, tablet). The extent of difference in the plasma concentration profiles simulated for Japanese and Caucasian using the PPK model under the same demographic condition was comparable with the results of the food effect study performed previously in Japan. The findings suggest that the difference in the plasma concentration profiles between Japanese and other countries' subjects was mainly due to the difference of food intake conditions under which the clinical trials were performed.",
author = "Shinji Tatami and Norio Yamamura and Akiko Sarashina and Yong, {Chan Loi} and Takashi Igarashi and Yusuke Tanigawara",
year = "2004",
language = "English",
volume = "19",
pages = "15--23",
journal = "Drug Metabolism and Pharmacokinetics",
issn = "1347-4367",
publisher = "Japanese Society for the Study of Xenobiotics",
number = "1",

}

TY - JOUR

T1 - Pharmacokinetic comparison of an angiotensin II receptor antagonist, telmisartan, in Japanese and western hypertensive patients using population pharmacokinetic method.

AU - Tatami, Shinji

AU - Yamamura, Norio

AU - Sarashina, Akiko

AU - Yong, Chan Loi

AU - Igarashi, Takashi

AU - Tanigawara, Yusuke

PY - 2004

Y1 - 2004

N2 - The objectives of this study were to develop a population pharmacokinetic (PPK) model for telmisartan based on the pooled data obtained from the different racial populations and then to identify the factors that affect the pharmacokinetics of telmisartan for the comparison between the regions. A PPK model was established based on the data of 1343 subjects in 12 clinical trials. The PK profiles of telmisartan were described with a 2-compartment model with first-order absorption. The obtained model could predict the observed plasma concentrations well. This PPK model suggested that CL/F was a function of age, dose, gender, race, alcohol consumption and liver function. A marked difference was observed in the plasma concentration profiles between Japanese and other countries' subjects. However, the effect of the factor "race" on CL/F was not large. In the present PPK model, "trial condition" affected all PK parameters except for V(2)/F. The condition differences were in food condition and formulation (Japanese: fed, capsule, US and EU: fasted, tablet). The extent of difference in the plasma concentration profiles simulated for Japanese and Caucasian using the PPK model under the same demographic condition was comparable with the results of the food effect study performed previously in Japan. The findings suggest that the difference in the plasma concentration profiles between Japanese and other countries' subjects was mainly due to the difference of food intake conditions under which the clinical trials were performed.

AB - The objectives of this study were to develop a population pharmacokinetic (PPK) model for telmisartan based on the pooled data obtained from the different racial populations and then to identify the factors that affect the pharmacokinetics of telmisartan for the comparison between the regions. A PPK model was established based on the data of 1343 subjects in 12 clinical trials. The PK profiles of telmisartan were described with a 2-compartment model with first-order absorption. The obtained model could predict the observed plasma concentrations well. This PPK model suggested that CL/F was a function of age, dose, gender, race, alcohol consumption and liver function. A marked difference was observed in the plasma concentration profiles between Japanese and other countries' subjects. However, the effect of the factor "race" on CL/F was not large. In the present PPK model, "trial condition" affected all PK parameters except for V(2)/F. The condition differences were in food condition and formulation (Japanese: fed, capsule, US and EU: fasted, tablet). The extent of difference in the plasma concentration profiles simulated for Japanese and Caucasian using the PPK model under the same demographic condition was comparable with the results of the food effect study performed previously in Japan. The findings suggest that the difference in the plasma concentration profiles between Japanese and other countries' subjects was mainly due to the difference of food intake conditions under which the clinical trials were performed.

UR - http://www.scopus.com/inward/record.url?scp=7444228708&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7444228708&partnerID=8YFLogxK

M3 - Article

C2 - 15499165

AN - SCOPUS:7444228708

VL - 19

SP - 15

EP - 23

JO - Drug Metabolism and Pharmacokinetics

JF - Drug Metabolism and Pharmacokinetics

SN - 1347-4367

IS - 1

ER -